Invitrogen™ Siplizumab Humanized Recombinant Human Monoclonal Antibody

Human Recombinant Monoclonal Antibody

Supplier:  Invitrogen™ MA541712

Catalog No. PIMA541712

Description

Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Siplizumab has been shown to cause depletion of T-cells. It is therefore considered to be an immunomodulator in clinical settings where the depletion of T-cells may have clinical benefits, such as certain autoimmune diseases and T-cell cancers. In addition, preclinical studies have also suggested that siplizumab, by binding to the CD2 receptor, may selectively produce cell death and reduce cancerous cells.

Specifications

• Antigen: Siplizumab Humanized
• Classification: Recombinant Monoclonal
• Conjugate: Unconjugated
• Gene Alias: MEDI-507
• Immunogen: Human CD2/LFA-2.
• Quantity: 100 μg
• Primary or Secondary: Primary
• Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
• Form: Liquid
• Target Molecule: Chemical

• Applications: ELISA, SDS-Page
• Concentration: 1.71 mg/mL
• Formulation: PBS with no preservative; pH 7.4
• Host Species: Human
• Purification Method: Protein A/G
• Regulatory Status: RUO
• Target Species: Human
• Product Type: Antibody
• Isotype: IgG1 κ